Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

Insmed Incorporated (INSM) announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its reversible inhibitor of dipeptidyl peptidase 1 (DPP1), brensocatib, for treating patients with non-cystic fibrosis bronchiectasis.With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Aug. 12, 2025.If approved, brensocatib will become the first and only approved treatment for bronchiectasis, a chronic lung disease with no approved treatments ...